Pleiotropic effects of netakimab in patients with psoriatic arthritis, spondylitis and comorbid metabolic syndrome or a new opportunity for weight control? Case report

Abstract

The article presents the results of studying the efficacy of netakimab (Efleira) in the complex treatment of patients with psoriasis, psoriatic arthritis, spondylitis and concomitant metabolic syndrome. The study included observations of clinical manifestations of diseases and changes after the use of netakimab. As a result of treatment, there was an improvement not only in clinical symptoms, but also in the metabolic syndrome parameters. In all 3 patients treated with netakimab, there was a decrease in the activity of sacroileitis, accompanied by weight loss, which indicates pleiotropic effect of this drug. The described clinical cases are of interest to rheumatologists, dermatologists, endocrinologists, therapists, general practitioners, and illustrate the successful use of netakimab as an interleukin-17 inhibitor.

Keywords

• psoriatic arthritis
• spondylitis
• metabolic syndrome
• comorbidity
• interleukin-17
• netakimab
• pleiotropic effect of netakimab
• treatment of obesity